BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Link Technologies Ltd Inks First License to RiboTask's Unlocked Nucleic Acid (UNA) Monomers


11/3/2009 11:33:51 AM

BELLSHILL, SCOTLAND, 3 November 2009: The ISO 9001:2000 certified specialist oligonucleotide reagent manufacturer, Link Technologies Ltd, is pleased to announce the commercialisation and launch of a range of unlocked-nucleic acid (UNA) monomers under license from RiboTask ApS, Denmark. Under the terms of the agreement Link are permitted to sell the four UNA monomer phosphoramidite reagents for use in research. No financial details of the agreement have been disclosed.

These UNA products enable the fine-tuning of the duplex thermodynamic stability of oligonucleotides with applications in areas such as improved siRNA gene silencing.

Professor Jesper Wengel, co-founder and Chairman of RiboTask, and inventor of the UNA technology, commented: “In our efforts to advance the UNA technology, we have initiated an active out-licensing strategy. As a first step towards realising this strategy we are excited to now work with Link Technologies on the marketing of UNA monomers. We are convinced that Link Technologies, with its proven product quality and commitment to new technology, is an ideal partner for RiboTask”.

Dr John Bremner, Business Development Director at Link Technologies, concurs: “We are delighted to be working with such an eminent scientist in the oligonucleotide field as Professor Wengel. These products offer exciting possibilities for siRNA research, further enhancing the unique set of tools we are able to offer our customers”. Patents for the therapeutic use of UNA oligonucleotides are held by MDRNA, Inc., Bothell, Washington,US.

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES